OSR Holdings, Inc. announced that Vaximm AG, an OSR Company, has entered into a non-binding term sheet with BCM Europe AG to explore a potential exclusive global licensing agreement for VXM01, Vaximm's first-in-class oral cancer immunotherapy platform.
The term sheet establishes a six-month exclusivity period for negotiations towards a definitive licensing agreement, subject to due diligence and Board approvals.
Proposed terms include a $20 million upfront payment for Vaximm and up to $815 million in milestone payments.
Financial Terms
$20 million upfront payment and up to $815 million in milestone payments for Vaximm under the potential licensing agreement.
Strategic Partnership
BCME positioned as a strategic financial intermediary, mirroring structured financing approaches used by other companies in the industry.
Innovative Collaboration
Contemplated collaboration aims to accelerate the development and global commercialization of VXM01 while retaining full ownership of intellectual property.
- The potential licensing agreement with BCM Europe AG could significantly advance the development and commercialization of VXM01, a promising oral T-cell immunotherapy platform for cancer treatment.
- The proposed structure with BCME as a financial intermediary reflects a shared commitment to maximizing the global opportunity for VXM01.
The term sheet between Vaximm AG and BCM Europe AG marks a crucial step towards potentially transforming cancer treatment through the global licensing of VXM01. The collaboration is expected to drive innovation and accelerate the commercialization of this groundbreaking oral immunotherapy platform.